Adaptive Biotechnologies Corp vs MobilEye Global Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while MobilEye Global Inc trades at $8.97 (market cap $7.54B). The key difference: MobilEye Global Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MBLY | |
|---|---|---|
Market Cap | $4.04B | $7.54B |
Sector | Health | Technology |
52-Week High | $25.45 | $15.54 |
52-Week Low | $12.30 | $6.56 |
Enterprise Value | $4.10B | $6.10B |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →